Why is AstraZeneca Mölndal important?

AstraZeneca's Mölndal site is one of three global R&D hubs (alongside Cambridge UK and Gaithersburg US) and a major manufacturing site. It anchors Western Swedish biotech employment, talent flow, and cluster gravity. Many of Gothenburg's mid-cap and emerging biotech operators have AstraZeneca alumni in their leadership.

What sectors are strongest in Gothenburg biotech?

Cardiovascular, renal, and metabolism therapeutics (AstraZeneca-driven), heart failure (AnaCardio), type-1 diabetes (Diamyd), cell and gene therapy emerging cohort, and translational research from University of Gothenburg and Sahlgrenska. The cluster has deep large-pharma DNA + growing emerging biotech tail.

City page

Gothenburg biotech and pharma directory

Gothenburg is the anchor of Western Swedish biotech, centered on AstraZeneca's Mölndal R&D site — one of AstraZeneca's three global research hubs and the country's largest single biopharma operation. The cluster includes AnaCardio (heart failure therapeutics), Diamyd Medical (type-1 diabetes vaccine), Sahlgrenska University Hospital and the University of Gothenburg as research anchors, plus emerging biotech in cell therapy, fibrosis, and cardiometabolic disease.

Evidence

Visible records5

Verified5

Categories4

Regulated sites2

Avg sources / record0.0

City view

Where does this city read strongest?

Therapeutics (2), Tools (1), and Research (1). Most visible records: Verigraft, Elicera Therapeutics, and AstraZeneca Gothenburg.

City view

Which standards and public evidence are already visible?

ISO-13485 (2) and FDA-Inspected (1). Latest review: 22 March 2026. Review cycle: March 2026.

City view

Why does this city matter?

This page brings visible companies and infrastructure records into one practical view of Gothenburg.

By category

Gothenburg by category

Jump into a category page filtered to this country only.

Therapeutics (2)Tools (1)Research (1)Diagnostics (1)

Full list

Gothenburg biotech and pharma directory

5 city records currently match the active filter.

Gothenburg regenerative-medicine company developing personalized tissue-engineered grafts and transplantation therapies from an advanced Swedish tissue-therapy platform.

Lead: Petter BjorkquistChief Executive Officer
Scale: Clinical tissue-therapy platform

Gothenburg clinical-stage immuno-oncology company developing cell and gene therapies including CAR-T and armed oncolytic-virus programs from its Swedish base.

Lead: Jamal El-MoslehCEO and Co-Founder
Scale: Clinical-stage cell and gene therapy platform

Gothenburg strategic science-centre anchor integrating discovery biology, translational research, and global biopharma development programs.

Lead: Pascal SoriotChief Executive Officer
Scale: Global biopharmaceutical research and development

Gothenburg life-science equipment headquarters anchoring Getinge's sterilization, isolator, and cleanroom infrastructure portfolio for regulated production environments.

Lead: Mattias PerjosPresident and CEO
Scale: Industrial Infrastructure

Gothenburg reproductive-health headquarters and production base combining IVF media, time-lapse imaging, and genomics-linked product operations inside the Vitrolife Group.

Lead: Bronwyn BrophyChief Executive Officer
Scale: Global Market

FAQ

Frequently asked questions

What biotech companies are in Gothenburg?: AstraZeneca Mölndal (one of AstraZeneca's three global R&D hubs — cardiovascular, renal, metabolism, oncology). AnaCardio (heart failure therapeutics). Diamyd Medical (type-1 diabetes vaccine). Plus mid-cap biotech and university spinouts anchored by University of Gothenburg and Sahlgrenska University Hospital.
Why is AstraZeneca Mölndal important?: AstraZeneca's Mölndal site is one of three global R&D hubs (alongside Cambridge UK and Gaithersburg US) and a major manufacturing site. It anchors Western Swedish biotech employment, talent flow, and cluster gravity. Many of Gothenburg's mid-cap and emerging biotech operators have AstraZeneca alumni in their leadership.
What sectors are strongest in Gothenburg biotech?: Cardiovascular, renal, and metabolism therapeutics (AstraZeneca-driven), heart failure (AnaCardio), type-1 diabetes (Diamyd), cell and gene therapy emerging cohort, and translational research from University of Gothenburg and Sahlgrenska. The cluster has deep large-pharma DNA + growing emerging biotech tail.

Related briefs

Briefs that mention Gothenburg

Market brief

Viral Vector CDMO Europe 2026: AAV, Adenovirus, Lentivirus

Where to manufacture viral vectors in Europe in 2026 — FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, Fuse Vectors, IDT Biologika — and how the European viral vector CDMO layer is structured.

Open brief

Market brief

Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway

A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.

Open brief

Market brief

Cell & Gene Therapy Europe 2026: CAR-T, Stem Cell, ATMP, Regenerative

A practical map of the European cell and gene therapy landscape in 2026 — CAR-T and TCR-T therapeutics, stem-cell and regenerative ATMPs, tissue engineering, plus the viral-vector CDMO and tools supply chain — across 26 operators in the directory.

Open brief

Next step

Read the city, then widen the view.

Use country and regional pages for wider context, and the company suggestion form for new candidate records.

Open country page Suggest a company